Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

BACKGROUND: Radium‐223 dichloride (Ra‐223) is a targeted alpha therapy that induces localized cytotoxicity in bone metastases. We evaluated the efficacy and safety of Ra‐223 plus hormonal therapy in hormone receptor‐positive (HR+), bone‐dominant metastatic breast cancer. METHODS: In this single‐cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Naoto T., Tahara, Rie K., Fujii, Takeo, Reuben, James M., Gao, Hui, Saigal, Babita, Lucci, Anthony, Iwase, Toshiaki, Ibrahim, Nuhad K., Damodaran, Senthil, Shen, Yu, Liu, Diane D., Hortobagyi, Gabriel N., Tripathy, Debu, Lim, Bora, Chasen, Beth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997080/
https://www.ncbi.nlm.nih.gov/pubmed/31849202
http://dx.doi.org/10.1002/cam4.2780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997080/
https://www.ncbi.nlm.nih.gov/pubmed/31849202
http://dx.doi.org/10.1002/cam4.2780

Ejemplares similares